Search clinical trials for: darunavir ritonavir raltegravir

Total 1145 results

Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation (RAPID)

HIV
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

HIV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

HIV Infections
Pfizer

Completed

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Biological Availability

Belgium
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
ViiV Healthcare

Completed

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

HIV-1 Infection

Spain
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

HIV-1 Infection

Spain
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)

HIV Infections | HIV-1 Infection
Merck Sharp & Dohme LLC

Terminated

A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

HIV
National Jewish Health
Merck Sharp & Dohme LLC

Completed

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

HIV

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Human Immunodeficiency Virus (HIV) Infection

Japan
University of Nebraska

Completed

Measurement of Plasma and Intracellular Concentrations of Raltegravir

HIV

United States
Fundacion para la Investigacion Biomedica del Hospital...
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis (LIVERAL)

Hepatitis C | Human Immunodeficiency Virus

Spain
Catholic University of the Sacred Heart

Completed

Raltegravir Switch for Toxicity or Adverse Events (RaSTA)

HIV Infections | HIV/AIDS | Antiretroviral Therapy

Italy
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain

HIV Infections

Spain
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Merck Sharp & Dohme LLC

Completed

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

HIV

Spain
University of South Florida
Merck Sharp & Dohme LLC; St. Joseph's Hospital, Florida

Completed

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

Virus Diseases | HIV

United States
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients (INROADS)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
A.O. Ospedale Papa Giovanni XXIII
San Raffaele University Hospital, Italy

Unknown

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection (PROBE2)

HIV Infection

Italy
Hospital Clinic of Barcelona

Completed

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients (RAL-LT-HIV)

Liver Transplantation | HIV Infections | Antiretroviral Therapy
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia

HIV Infection

United States
Canadian Immunodeficiency Research Collaborative
National Institutes of Health (NIH)

Completed

Integrase Inhibitor (MK-0518) Viral Decay

HIV Infections

Canada
Kristine Patterson, MD
Merck Sharp & Dohme LLC

Completed

A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

HIV | AIDS

United States
Community Research Initiative of New England

Completed

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors (DVD)

HIV Infections

United States
Janssen Research & Development, LLC

Completed

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Healthy

Belgium
Karolinska Institutet
Karolinska University Hospital; Pfizer

Recruiting

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

COVID-19 | Post-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | POTS - Postural Orthostatic Tachycardia Syndrome | Postinfectious Inflammation | Postinfectious Disorder

Sweden
Drugs for Neglected Diseases
University of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation and other collaborators

Completed

Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB

Acquired Immunodeficiency Syndrome | Tuberculosis

South Africa
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
Institut de Médecine et d'Epidémiologie Appliquée...

Completed

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts (DATA)

HIV-1 Infection | Immunosuppression-related Infectious Disease

France
Imperial College London

Completed

The Raltegravir and Ribavirin Pharmacokinetics (PK) Study

HIV Infections

United Kingdom
Therapeutic Concepts
Janssen Scientific Affairs, LLC

Unknown

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)

HIV Positive

United States
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

HIV Infections

Spain
Helen Reynolds

Completed

The Effect of Antacids and Multivitamins on Raltegravir

HIV

United Kingdom
University of California, San Diego
Merck Sharp & Dohme LLC; Abbott; California HIV/AIDS Research Program

Completed

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

HIV Infections

United States
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
Peking Union Medical College
Ministry of Science and Technology of the People´s Republic of China

Unknown

Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection

AIDS/HIV PROBLEM

China
University of California, San Francisco

Completed

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut (PLUS)

HIV Infections

United States
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC

Completed

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

Fatty Liver | HIV | Nonalcoholic Steatohepatitis

Canada
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects

Healthy Participants

China
University of British Columbia
Gilead Sciences

Completed

Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (QuaDar)

HIV Infection

Canada
Centre de Recherches et d'Etude sur la Pathologie...

Completed

Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection. (RADAR)

HIV Infections | HIV-1 Infection

France
Tibotec Pharmaceuticals, Ireland

Completed

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

HIV-1
Association Pour la Recherche en Infectiologie

Unknown

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients (NNNB)

HIV

France
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

HIV Infections

United States
National Institutes of Health Clinical Center (CC)

Completed

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Completed

The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)

HIV Infection
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (RALAM-RollOver)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen (RALAM-II)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
Tibotec Pharmaceuticals, Ireland
Raltegravir is provided by Merck.

Completed

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

HIV Infections
Hospitales Universitarios Virgen del Rocío

Completed

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (RAET)

HIV Infections | HIV-1 Infection

Spain
ANRS, Emerging Infectious Diseases
Janssen Pharmaceuticals

Completed

Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (MOBIDIP)

HIV Infection

Cameroon, Burkina Faso, Senegal

3

Subscribe